Skip to main content
. Author manuscript; available in PMC: 2011 Jun 1.
Published in final edited form as: Gynecol Oncol. 2010 Mar 26;117(3):467–472. doi: 10.1016/j.ygyno.2010.02.008

Table 2. Survival comparisons by best RECIST response (1st phase I trial).

Response N Deaths Median OS in months (95%CI) (%) Survival at 1 Year (95%CI) P-value
All patients 85 58 7.9 (6.1 - 10.1) 0.29 (0.21 - 0.44)
CR/PR/SD vs. 25 10 14.9 (10.1 - NA) 0.51 (0.33 - 0.82) <0.0001
 PD/Not evaluable 60 48 6.01 (4.5 - 7.9) 0.21 (0.12 - 0.37)
PD/Not evaluable vs. 60 48 6.01 (4.5 - 7.9) 0.21 (0.12 - 0.37) 0.004
 SD 19 9 11.0 (8.9 - NA) 0.42 (0.22 - 0.81)

Abbreviations: OS = overall survival, CI = confidence interval, CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, NA = not available (insufficient events/deaths to define an upper boundary)